Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 10/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311861 | 0.94 | CETP (0.45) | CETPSLC6A4HTR2AKCNH2MC4R | |
| SCHEMBL7082558 | 0.88 | CETP (0.47) | CETPP2RX7SLC6A4HTR2AKCNH2 | |
| SCHEMBL6312922 | 0.87 | CETP (0.46) | CETPP2RX7SLC6A4HTR2AKCNH2 | |
| SCHEMBL6304765 | 0.85 | CETP (0.63) | CETPSLC6A4HTR2AKCNH2TLR8 | |
| SCHEMBL6304217 | 0.85 | CETP (0.44) | CETP | |
| SCHEMBL6304082 | 0.85 | CETP (0.40) | CETPSLC6A4ARSLC6A2SLC6A3 | |
| SCHEMBL6306162 | 0.84 | CETP (0.55) | CETP | |
| SCHEMBL6312126 | 0.83 | CETP (0.47) | CETP | |
| SCHEMBL6304748 | 0.83 | CETP (0.44) | CETP | |
| SCHEMBL6306918 | 0.83 | CETP (0.45) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861561-B2 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | claimed |
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-12-04 | — | — | US | claimed |
| US-6482862-B1 | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, MTTP | CETP 1/4885P2RX7 4072/4885SLC6A4 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.